Exhibit 99.1

FOR IMMEDIATE RELEASE

Oragenics Completes $1.175 million Financing

ALACHUA, FL (December 19, 2005): Oragenics, Inc. (AMEX:ONI) announced today that
it has completed its anticipated equity based financing with a group of
accredited investors. The $1,175,000 financing provides for the issuance of
2,937,500 shares of common stock at a price of $0.40 per share and the issuance
of an equal number of warrants to purchase shares of common stock that will be
exercisable at $0.60 per share. As stated by Oragenics' CFO, Paul Hassie, "This
financing will help us maintain our progress with the clinical program for our
SMaRT replacement therapy technology and the preclinical work for our MU 1140
antibiotic technology."

Neither the shares of common stock, nor the shares of common stock underlying
the warrants are registered under the Securities Act of 1933, as amended, and
may not be offered or sold in the United States absent registration or an
applicable exemption from registration requirements. However, the company will
file a resale registration statement with the Securities and Exchange Commission
relating to the shares of common stock to be issued in the transaction and the
shares of common stock to be issued upon exercise of the warrants within forty
five days of the closing. This press release does not constitute an offer to
sell, or the solicitation of an offer to buy, any securities and shall not
constitute an offer, solicitation or sale in any jurisdiction in which such
offer, solicitation or sale would be unlawful.

The Company has also announced the resignation of Mento A. Soponis from its
Board of Directors and the election of George Hawes to Board of Directors. As
stated by Oragenics' Chairman, David Gury, "We wish Chuck Soponis well in his
new endeavors and appreciate his contributions, as a director and officer, to
the development of our Company. We also look forward to working with George
Hawes who is a seasoned veteran in business and international finance." Mr.
Hawes currently serves as a director for Gentry Resources Ltd. and Midway Gold
Corp., both Canadian based public companies, and Proginet Corp., a publicly
traded computer software company.

About Oragenics

Oragenics is focused on the development of novel technologies and products to
address significant, unmet medical needs. Oragenics' strategy is to license and
develop products through human proof-of-concept studies prior to partnering with
major pharmaceutical, biotechnology or healthcare product firms for advanced
clinical development and commercialization. Upon completion of the private
placement financing Oragenics plans to continue its development of the following
products, which address potentially major market opportunities:

      o     SMaRT Replacement Therapy is a single, painless topical treatment
            that has the potential to offer life-long protection from most tooth
            decay.

      o     MU 1140 is a novel antibiotic with activity against many
            Gram-positive bacteria including multidrug resistant Staphylococcus
            aureus and Enterococcus faecalis. MU 1140 has a number of other
            characteristics that suggest its potential use in the treatment of a
            variety of infectious diseases.


For more information about Oragenics, please consult the company's website at
www.oragenics.com.

Safe Harbor Statement: Under the Private Securities Litigation Reform Act of
1995: This release includes forward-looking statements that reflect Oragenics'
current views with respect to future events and financial performance. These
forward-looking statements are based on management's beliefs and assumptions and
information currently available. The words "believe," "expect," "anticipate,"
"intend," "estimate," "project" and similar expressions that do not relate
solely to historical matters identify forward-looking statements. Investors
should be cautious in relying on forward-looking statements because they are
subject to a variety of risks, uncertainties, and other factors that could cause
actual results to differ materially from those expressed in any such
forward-looking statements. These factors include, but are not limited to those
set forth in our most recently filed annual report on Form 10-KSB and quarterly
report on Form 10-QSB, and other factors detailed from time to time in filings
with the Securities and Exchange Commission. We expressly disclaim any
responsibility to update forward-looking statements.



- --------------------------
Contact:
     Oragenics, Inc.
     Paul A. Hassie, 386-418-4018 X232
     www.oragenics.com


                                      # # #